Compare FSFG & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSFG | FENC |
|---|---|---|
| Founded | 2008 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.5M | 258.5M |
| IPO Year | 2008 | 2001 |
| Metric | FSFG | FENC |
|---|---|---|
| Price | $32.64 | $7.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $31.50 | $13.50 |
| AVG Volume (30 Days) | 17.7K | ★ 148.5K |
| Earning Date | 01-27-2026 | 11-13-2025 |
| Dividend Yield | ★ 1.95% | N/A |
| EPS Growth | ★ 67.68 | N/A |
| EPS | ★ 3.32 | N/A |
| Revenue | ★ $84,223,000.00 | $38,790,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $70.97 |
| P/E Ratio | $9.90 | ★ N/A |
| Revenue Growth | ★ 23.59 | N/A |
| 52 Week Low | $21.63 | $4.68 |
| 52 Week High | $33.35 | $9.92 |
| Indicator | FSFG | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 59.45 | 47.12 |
| Support Level | $32.28 | $7.50 |
| Resistance Level | $33.35 | $7.83 |
| Average True Range (ATR) | 0.46 | 0.28 |
| MACD | -0.03 | 0.03 |
| Stochastic Oscillator | 63.40 | 49.23 |
First Savings Financial Group Inc provides various banking services to individuals and business customers in southern Indiana. The bank accepts deposits from the general public & uses those funds, along with other borrowings, mainly to originate a residential mortgage, commercial mortgage, construction, commercial business, & consumer loans, and to a lesser extent, to invest in mortgage-backed securities and other debt securities. The company conducts lending and deposit activities mainly with individuals and small businesses in its market area. The bank operates in two segments: core banking, which accounts for the majority of revenue, and SBA lending.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.